We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunomedics Up as Breast Cancer Drug Study Shows Efficacy
Read MoreHide Full Article
Shares of clinical-stage biopharmaceutical company, Immunomedics, Inc. , surged 99.79% after it announced that the late-stage study on lead candidate sacituzumab govitecan will be halted due to compelling evidence of efficacy.
The decision was based on the unanimous recommendation by the independent Data Safety Monitoring Committee (DSMC) following its recent routine review of the ASCENT study.
The phase III confirmatory ASCENT study is designed to validate the promising safety and efficacy data of sacituzumab govitecan observed in a phase II study of heavily pretreated patients with metastatic triple-negative breast cancer (mTNBC). The primary endpoint of the study is progression-free survival and the secondary endpoints include overall survival and objective response rate, among others.
Per the chairperson of the independent DSMC, remarkable results were observed across multiple endpoints in the ASCENT study. These results warranted early discontinuation of the study and are indicative of a potential major advancement in the treatment of this devastating disease.
Investors cheered the news.
We remind investors that the FDA previously granted Breakthrough Therapy designation to sacituzumab govitecan for the same indication.
In May 2018, the company submitted a Biologics License Application (“BLA”) to the FDA for sacituzumab govitecan for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease. The BLA was accepted for filing and the original application was granted Priority Review with a target action date in January 2019. However, the FDA then issued a Complete Response Letter ("CRL") to the BLA. Thereafter, the company developed a detailed plan to address the chemistry, manufacturing, and control (“CMC”) matters raised in the CRL. In November 2019, the company resubmitted its BLA to the FDA. The BLA was accepted for filing and the FDA set a new target action date of Jun 2, 2020.
A potential approval of the candidate will be a significant boost for the company, which currently has no approved products in its portfolio.
Immunomedics’ shares have lost 11.3% in the year so far compared with the industry’s decline of 11.6%.
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Immunomedics Up as Breast Cancer Drug Study Shows Efficacy
Shares of clinical-stage biopharmaceutical company, Immunomedics, Inc. , surged 99.79% after it announced that the late-stage study on lead candidate sacituzumab govitecan will be halted due to compelling evidence of efficacy.
The decision was based on the unanimous recommendation by the independent Data Safety Monitoring Committee (DSMC) following its recent routine review of the ASCENT study.
The phase III confirmatory ASCENT study is designed to validate the promising safety and efficacy data of sacituzumab govitecan observed in a phase II study of heavily pretreated patients with metastatic triple-negative breast cancer (mTNBC). The primary endpoint of the study is progression-free survival and the secondary endpoints include overall survival and objective response rate, among others.
Per the chairperson of the independent DSMC, remarkable results were observed across multiple endpoints in the ASCENT study. These results warranted early discontinuation of the study and are indicative of a potential major advancement in the treatment of this devastating disease.
Investors cheered the news.
We remind investors that the FDA previously granted Breakthrough Therapy designation to sacituzumab govitecan for the same indication.
In May 2018, the company submitted a Biologics License Application (“BLA”) to the FDA for sacituzumab govitecan for the treatment of patients with mTNBC who have received at least two prior therapies for metastatic disease. The BLA was accepted for filing and the original application was granted Priority Review with a target action date in January 2019. However, the FDA then issued a Complete Response Letter ("CRL") to the BLA. Thereafter, the company developed a detailed plan to address the chemistry, manufacturing, and control (“CMC”) matters raised in the CRL. In November 2019, the company resubmitted its BLA to the FDA. The BLA was accepted for filing and the FDA set a new target action date of Jun 2, 2020.
A potential approval of the candidate will be a significant boost for the company, which currently has no approved products in its portfolio.
Immunomedics’ shares have lost 11.3% in the year so far compared with the industry’s decline of 11.6%.
However, competition is stiff in this space from Roche (RHHBY - Free Report) , Novartis (NVS - Free Report) and Merck (MRK - Free Report) .
Immunomedics currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>